- Investing.com
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
तुलना करने के लिए मीट्रिक्स | MGNX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMGNXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.5x | −0.6x | −0.6x | |
PEG अनुपात | −0.06 | 0.07 | 0.00 | |
क़ीमत/बुक | 1.6x | 3.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.9x | 9.6x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 71.4% | 47.9% | 42.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.7% | 5.8% | अनलॉक करें |